Inflammation and its genesis in cystic fibrosis

Pediatric Pulmonology

Volumn 50, Issue , 2015, Pages S39-S56

  Nichols, David P ^a,b,c   Chmiel, James F ^d  

^a Nutrition Obesity Research Center at the University of Colorado   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c DEPARTMENT OF MEDICINE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

anti inflammatory; cystic fibrosis; elastase; inflammation; neutrophil

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTIINFLAMMATORY AGENT; BICARBONATE; CERAMIDE; CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOCOSAHEXAENOIC ACID; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; MUCIN; THIOCYANATE; TRANSCRIPTION FACTOR NRF2; CFTR PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID;

AIRWAY OBSTRUCTION; AIRWAY SMOOTH MUSCLE CELL; AUTOPHAGY; BACTERIAL INFECTION; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; EPITHELIUM CELL; EXERCISE; EXTRACELLULAR TRAP; HUMAN; IMMUNOMODULATION; LUNG CLEARANCE; LYMPHOCYTE; MACROPHAGE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXIDATION REDUCTION STATE; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFLAMMATION; REVIEW; ANIMAL; BRONCHIECTASIS; CHEMISTRY; CHRONIC DISEASE; COMPLICATION; CYTOLOGY; IMMUNOLOGY; INFLAMMATION; LUNG; METABOLISM; MOUSE; NEUTROPHIL; OXIDATIVE STRESS; PHYSIOLOGY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL;

AIRWAY OBSTRUCTION; ANIMALS; BACTERIAL INFECTIONS; BRONCHIECTASIS; CHRONIC DISEASE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; INFLAMMATION; LIPIDS; LUNG; LYMPHOCYTES; MACROPHAGES; MICE; MYOCYTES, SMOOTH MUSCLE; NEUTROPHILS; NF-KAPPA B; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 84941102510     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23242     Document Type: Review

References (210)

1. Davis PB, Drumm M, Konstan MW,. Cystic fibrosis. State of the art. Am J Resp Crit Care Med 1996; 154: 1229-1256.
2. Bedrossian CW, Greenberg SD, Singer DB, Jansen JJ, Rosenberg HS,. The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups. Hum Pathol 1976; 7: 195-204.
3. Meyerholz DK, Stoltz DA, Namati E, Ramachandran S, Pezzulo AA, Smith AR, Rector MV, Suter MJ, Kao S, McLennan G, et al., Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children. Am J Respir Crit Care Med 2010; 182: 1251-1261.
4. Chmiel JF, Konstan MW, Berger M,. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 2002; 23: 5-27.
5. Chmiel JF, Davis PB,. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? Respir Res 2003; 4: 8-21.
6. Sly PD, Gangell CL, Chen L, Ware RS, Ranganathan S, Mott LS, Murray CP, Stick SM, AREST CF Investigators,. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013; 368: 1963-1970.
7. Chmiel JF, Konstan MW,. Inflammation in the cystic fibrosis lung. In:, Allen JL, Panitch HB, Rubenstein RC, editors. Cystic Fibrosis. New York: Informa Healthcare USA, Inc.; 2010. pp 57-77.
8. Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, Ghnaim H, Berger M,. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152: 2111-2118.
9. Moser C, Jensen PØ, Pressler T, Frederiksen B, Lanng S, Kharazmi A, Koch C, Høiby N,. Serum concentrations of GM-CSF and G-CSF correlate with Pseudomonas aeruginosa lung infection. APMIS 2005; 113: 400-409.
10. Koller DY, Nething I, Otto J, Urbanek R, Eichler I,. Cytokine concentrations in sputum from patients with cystic fibrosis and their relation to eosinophil activity. Am J Respir Crit Care Med 1997; 155: 1050-1054.
11. Tiringer K, Treis A, Kanolzer S, Witt C, Ghanim B, Gruber S, Schmidthaler K, Renner S, Dehlink E, Nachbaur E, et al., Differential expression of IL-33 and HMGB1 in the lungs of stable cystic fibrosis patients. Eur Respir J 2014; 44: 802-805.
12. Roussel L, Farias R, Rousseau S,. IL-33 is expressed in epithelia from patients with cystic fibrosis and potentiates neutrophil recruitment. J Allergy Clin Immunol 2013; 131: 913-916.
13. Hostoffer RW, Krukovets I, Berger M,. Enhancement by tumor necrosis factor-alpha of Fc alpha receptor expression and IgA-mediated superoxide generation and killing of Pseudomonas aeruginosa by polymorphonuclear leukocytes. J Infect Dis 1994; 170: 82-87.
14. Klebanoff SJ, Vadas MA, Harlan JM, Sparks LH, Gamble JR, Agosti JM, Waltersdorph AM,. Stimulation of neutrophils by tumor necrosis factor. J Immunol 1986; 136: 4220-4225.
15. Cerami A, Beutler B,. The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today 1988; 9: 28-31.
16. Saba S, Soong G, Greenberg S, Prince A,. Bacterial stimulation of epithelial G-CSF and GM-CSF expression promotes PMN survival in CF airways. Am J Respir Cell Mol Biol 2002; 27: 561-567.
17. Bonfield TL, Konstan MW, Berger M,. Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol 1999; 104: 72-78.
18. Grasemann H, Michler E, Wallot M, Ratjen F,. Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol 1997; 24: 173-177.
19. Balfour-Lynn IM, Laverty A, Dinwiddie R,. Reduced upper airway nitric oxide in cystic fibrosis. Arch Dis Child 1996; 75: 319-322.
20. Karp CL, Flick LM, Park KW, Softic S, Greer TM, Keledjian R, Yang R, Uddin J, Guggino WB, Atabani SF, et al., Defective lipoxin-mediated anti inflammatory activity in the cystic fibrosis airway. Nat Immunol 2004; 5: 388-392.
21. Moss RB, Bocian RC, Hsu YP, Dong YJ, Kemna M, Wei T, Gardner P,. Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). Clin Exp Immunol 1996; 106: 374-388.
22. Elmer HL, Brady KG, Drumm ML, Kelley TJ,. Nitric oxide-mediated regulation of transepithelial sodium and chloride transport in murine nasal epithelium. Am J Physiol 1999; 276: L466-L473.
23. Mhanna MJ, Ferkol T, Martin RJ, Dreshaj IA, van Heeckeren AM, Kelley TJ, Haxhiu MA,. Nitric oxide deficiency contributes to impairment of airway relaxation in cystic fibrosis mice. Am J Respir Cell Mol Biol 2001; 24: 621-626.
24. Smith AW, Green J, Eden CE, Watson ML,. Nitric oxide-induced potentiation of the killing of Burkholderia cepacia by reactive oxygen species: implications for cystic fibrosis. J Med Microbiol 1999; 48: 419-423.
25. Sato Y, Walley KR, Klut ME, English D, D'yachkova Y, Hogg JC, van Eeden SF,. Nitric oxide reduces the sequestration of polymorphonuclear leukocytes in lung by changing deformability and CD18 expression. Am J Respir Crit Care Med 1999; 159: 1469-1476.
26. Kube D, Sontich U, Fletcher D, Davis PB,. Proinflammatory cytokine responses to P. Aeruginosa infection in human airway epithelial cell lines. Am J Physiol Lung Cell Mol Physiol 2001; 280: L493.
27. - channel function. Am J Physiol Lung Cell Mol Physiol 2001; 281: L71.
28. Perez A, Issler AC, Cotton CU, Kelley TJ, Verkman AS, Davis PB,. CFTR inhibition mimics the cystic fibrosis inflammatory profile. Am J Physiol Lung Cell Mol Physiol 2007; 292: L383-L395.
29. Saadane A, Soltys J, Berger M,. Role of IL-10 deficiency in excessive nuclear factor-kappaB activation and lung inflammation in cystic fibrosis transmembrane conductance regulator knockout mice. J Allergy Clin Immunol 2005; 115: 405-411.
30. DiMango E, Ratner AJ, Bryan R, Tabibi S, Prince A,. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest 1998; 101: 2598-2605.
31. Venkatakrishnan A, Stecenko AA, King G, Blackwell TR, Brigham KL, Christman JW, Blackwell TS,. Exaggerated activation of nuclear factor-kappaB and altered IkappaB-beta processing in cystic fibrosis bronchial epithelial cells. Am J Respir Cell Mol Biol 2000; 23: 396-403.
32. Parker D, Cohen TS, Alhede M, Harfenist BS, Martin FJ, Prince A,. Induction of type I interferon signaling by Pseudomonas aeruginosa is diminished in cystic fibrosis epithelial cells. Am J Respir Cell Mol Biol 2012; 46: 6-13.
33. Kelley TJ, Elmer HL,. In vivo alterations of IFN regulatory factor-1 and PIAS1 protein levels in cystic fibrosis epithelium. J Clin Invest 2000; 106: 403-410.
34. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW,. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151: 1075-1082.
35. Grassmé H, Jendrossek V, Riehle A, von Kürthy G, Berger J, Schwarz H, Weller M, Kolesnick R, Gulbins E,. Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat Med 2003; 9: 322-330.
36. Teichgräber V, Ulrich M, Endlich N, Riethmüller J, Wilker B, De Oliveira-Munding CC, van Heeckeren AM, Barr ML, von Kürthy G, Schmid KW, et al., Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008; 14: 382-391.
37. Becker KA, Tümmler B, Gulbins E, Grassmé H,. Accumulation of ceramide in the trachea and intestine of cystic fibrosis mice causes inflammation and cell death. Biochem Biophys Res Commun 2010; 403: 368-374.
38. Guilbault C, De Sanctis JB, Wojewodka G, Saeed Z, Lachance C, Skinner TA, Vilela RM, Kubow S, Lands LC, Hajduch M, et al., Fenretinide corrects newly found ceramide deficiency in cystic fibrosis. Am J Respir Cell Mol Biol 2008; 38: 47-56.
39. Guilbault C, Wojewodka G, Saeed Z, Hajduch M, Matouk E, De Sanctis JB, Radzioch D,. Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide. Am J Respir Cell Mol Biol 2009; 41: 100-106.
40. Worgall TS., Lipid metabolism in cystic fibrosis. Curr Opin Clin Nutr Metab Care 2009; 12: 105-109.
41. Becker KA, Riethmüller J, Zhang Y, Gulbins E,. The role of sphingolipids and ceramide in pulmonary inflammation in cystic fibrosis. Open Respir Med J 2010; 4: 39-47.
42. Nährlich L, Mainz JG, Adams C, Engel C, Herrmann G, Icheva V, Lauer J, Deppisch C, Wirth A, Unger K, et al., Therapy of CF-patients with amitriptyline and placebo-a randomised, double blind, placebo-controlled phase IIb multicenter, cohort-study. Cell Physiol Biochem 2013; 31: 505-512.
43. White NM, Jiang D, Burgess JD, Bederman IR, Previs SF, Kelley TJ,. Altered cholesterol homeostasis in cultured and in vivo models of cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2007; 292: L476-L486.
44. Fang D, West RH, Manson ME, Ruddy J, Jiang D, Previs SF, Sonawane ND, Burgess JD, Kelley TJ,. Increased plasma membrane cholesterol in cystic fibrosis cells correlates with CFTR genotype and depends on de novo cholesterol synthesis. Respir Res 2010; 11: 61.
45. Manson ME, Corey DA, Bederman I, Burgess JD, Kelley TJ,. Regulatory role of β-arrestin-2 in cholesterol processing in cystic fibrosis epithelial cells. J Lipid Res 2012; 53: 1268-1276.
46. Rymut SM, Ivy T, Corey DA, Cotton CU, Burgess JD, Kelley TJ,. Reduced EPAC1 activity leads to slowed microtubule polymerization in cystic fibrosis epithelial cells. Am J Respir Cell Mol Biol 2015;[in press].
47. Rymut SM, Harker A, Corey DA, Burgess JD, Sun H, Clancy JP, Kelley TJ,. Reduced microtubule acetylation in cystic fibrosis epithelial cells. Am J Physiol Lung Cell Mol Physiol 2013; 305: L419-L431.
48. Welsh MJ, Smith JJ,. CAMP stimulation of HCO3-secretion across airway epithelia. JOP 2001; 2: 291-293.
49. Coakley RD, Grubb BR, Paradiso AM, Gatzy JT, Johnson LG, Kreda SM, O'Neal WK, Boucher RC,. Abnormal surface liquid pH regulation by cultured cystic fibrosis bronchial epithelium. Proc Natl Acad Sci USA 2003; 100: 16083-16088.
50. Shamsuddin AK, Quinton PM,. Native small airways secrete bicarbonate. Am J Respir Cell Mol Biol 2014; 50: 796-804.
51. Song Y, Salinas D, Nielson DW, Verkman AS,. Hyperacidity of secreted fluid from submucosal glands in early cystic fibrosis. Am J Physiol Cell Physiol 2006; 290: C741-C749.
52. Tan HL, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC,. The Th17 pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med 2011; 184: 252-258.
53. Regamey N, Jeffery PK, Alton EW, Bush A, Davies JC,. Airway remodelling and its relationship to inflammation in cystic fibrosis. Thorax 2011; 66: 624-649.
54. Becker MN, Sauer MS, Muhlebach MS, Hirsh AJ, Wu Q, Verghese MW, Randell SH,. Cytokine secretion by cystic fibrosis airway epithelial cells. Am J Respir Crit Care Med 2004; 169: 645-653.
55. Ziady AG, Sokolow A, Shank S, Corey D, Myers R, Plafker S, Kelley TJ,. Interaction with CREB binding protein modulates the activities of Nrf2 and NF-kappaB in cystic fibrosis airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2012; 302: L1221-L1231.
56. 2 and inflammatory cytokine production. PLoS ONE 2008; 3: e3367.
57. Berube J, Roussel L, Nattagh L, Rousseau S,. Loss of cystic fibrosis transmembrane conductance regulator function enhances activation of p38 and ERK MAPKs, increasing interleukin-6 synthesis in airway epithelial cells exposed to Pseudomonas aeruginosa. J Biol Chem 2010; 285: 22299-22307.
58. Moriceau S, Lenoir G, Witko-Sarsat V,. In cystic fibrosis homozygotes and heterozygotes, neutrophil apoptosis is delayed and modulated by diamide or roscovitine: evidence for an innate neutrophil disturbance. Journal Innate Immun 2010; 2: 260-266.
59. Gaggar A, Jackson PL, Noerager BD, O'Reilly PJ, McQuaid DB, Rowe SM, Clancy JP, Blalock JE,. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol 2008; 180: 5662-5669.
60. Marguet C, Jouen-Boedes F, Dean TP, Warner JO,. Bronchoalveolar cell profiles in children with asthma, infantile wheeze, chronic cough, or cystic fibrosis. Am J Respir Crit Care Med 1999; 159: 1533-1540.
61. Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan PD,. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995; 310: 1571-1572.
62. Pillarisetti N, Williamson E, Linnane B, Skoric B, Robertson CF, Robinson P, Massie J, Hall GL, Sly P, Stick S, et al., Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011; 184: 75-81.
63. Sly PD, Brennan S, Gangell C, de Klerk N, Murray C, Mott L, Stick SM, Robinson PJ, Robertson CF, Ranganathan SC, et al., Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009; 180: 146-152.
64. Wine JJ., The development of lung disease in cystic fibrosis pigs. Sci Transl Med 2010; 2: 29ps20.
65. Stoltz DA, Meyerholz DK, Pezzulo AA, Ramachandran S, Rogan MP, Davis GJ, Hanfland RA, Wohlford-Lenane C, Dohrn CL, et al., Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med 2010; 2: 29ra31.
66. Keiser NW, Birket SE, Evans IA, Tyler SR, Crooke AK, Sun X, Zhou W, Nellis JR, Stroebele EK, Chu KK, et al., Defective innate immunity and hyper-inflammation in newborn CFTR-knockout ferret lungs. Am J Respir Cell Mol Biol 2015; 52683-52694.
67. Sun X, Olivier AK, Liang B, Yi Y, Sui H, Evans TI, Zhang Y, Zhou W, Tyler SR, Fisher JT, et al., Lung phenotype of juvenile and adult cystic fibrosis transmembrane conductance regulator-knockout ferrets. Am J Respir Cell Mol Biol 2014; 50: 502-512.
68. van Heeckeren AM, Schluchter MD, Drumm ML, Davis PB,. Role of Cftr genotype in the response to chronic Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol 2004; 287: L944-L952.
69. van Heeckeren A, Walenga R, Konstan MW, Bonfield T, Davis PB, Ferkol T,. Excessive inflammatory response on cystic fibrosis mice to bronchopulmonary infection with P. Aeruginosa. J Clin Invest 1997; 100: 2810-2815.
70. Siegmann N, Worbs D, Effinger F, Bormann T, Gebhardt M, Ulrich M, Wermeling F, Müller-Hermelink E, Biedermann T, Tighe M, et al., Invariant natural killer T (iNKT) cells prevent autoimmunity, but induce pulmonary inflammation in cystic fibrosis. Cell Physiol Biochem 2014; 34: 56-70.
71. Peters-Hall JR, Brown KJ, Pillai DK, Tomney A, Garvin LM, Wu X, Rose MC,. Quantitative proteomics reveals an altered cystic fibrosis in vitro bronchial epithelial secretome. Am J Respir Cell Mol Biol 2015;[In press].
72. Roussel L, Rousseau S,. IL-17 primes airway epithelial cells lacking functional CFTR in increase NOD1 responses. Biochem Biophys Res Commun 2010; 391: 505-509.
73. Tirouvanziam R, de Bentzmann S, Hubeau C, Hinnrasky J, Jacquot J, Péault B, Puchelle E,. Inflammation and infection in naive human cystic fibrosis airway grafts. Am J Respir Cell Mol Biol 2000; 23: 121-127.
74. Mueller C, Braag SA, Keeler A, Hodges C, Drumm M, Flotte TR,. Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses. Am J Respir Cell Mol Biol 2011; 44: 922-929.
75. Madan JC, Koestler DC, Stanton BA, Davidson L, Moulton LA, Housman ML, Moore JH, Guill MF, Morrison HG, Sogin ML, et al., Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. MBio 2012: 3.
76. Cox MJ, Allgaier M, Taylor B, Baek MS, Huang YJ, Daly RA, Karaoz U, Andersen GL, Brown R, Fujimura KE, et al., Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS ONE 2010; 5: e11044.
77. Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, Ranganathan SC, Waters VJ, Ratjen FA,. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. Ann Am Thorac Soc 2014; 11: 1120-1129.
78. Zemanick ET, Wagner BD, Robertson CE, Stevens MJ, Szefler SJ, Accurso FJ, Sagel SD, Harris JK,. Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods. Ann Am Thorac Soc 2015; 12: 221-229.
79. Gould NS, Gauthier S, Kariya CT, Min E, Huang J, Brian DJ,. Hypertonic saline increases lung epithelial lining fluid glutathione and thiocyanate: two protective CFTR-dependent thiols against oxidative injury. Respir Res 2010; 27: 119.
80. Reeves EP, Williamson M, O'Neill SJ, Greally P, McElvaney NG,. Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med 2011; 183: 1517-1523.
81. Ratjen F, Saiman L, Mayer-Hamblett N, Lands LC, Kloster M, Thompson V, Emmett P, Marshall B, Accurso F, Sagel S, et al., Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest 2012; 142: 1259-1266.
82. Ribeiro CM, Hurd H, Wu Y, Martino ME, Jones L, Brighton B, Boucher RC, O'Neal WK,. Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia. PLoS ONE 2009; 4: e5806.
83. Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P,. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun 2006; 350: 977-982.
84. Haghi M, Saadat A, Zhu B, Colombo G, King G, Young PM, Traini D,. Immunomodulatory effects of a Low-dose clarithromycin-based macrolide solution pressurised metered dose inhaler. Pharm Res 2015; 32: 2144-2153.
85. Bensman TJ, Nguyen AN, Rao AP, Beringer PM,. Doxycycline exhibits anti-inflammatory activity in CF bronchial epithelial cells. Pulm Pharmacol Ther 2012; 25: 377-382.
86. Obad J, Suskovic J, Kos B,. Antimicrobial activity of ibuprofen: new perspectives on an "old" non-antibiotic drug. Eur J Pharm Sci 2015; 71: 93-98.
87. Elvers KT, Wright SJ,. Antibacterial activity of the anti-inflammatory compound ibuprofen. Lett Appl Microbiol 1995; 20: 82-84.
88. Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, Sagel SD, Khan U, Mayer-Hamblett N, Van Dalfsen JM, et al., Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 2014; 190: 175-184.
89. Pohl K, Hayes E, Keenan J, Henry M, Meleady P, Molloy K, Jundi B, Bergin DA, McCarthy C, McElvaney OJ, et al., A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy. Blood 2014; 124: 999-1009.
90. Yoshimura K, Nakamura H, Trapnell BC, Chu CS, Dalemans W, Pavirani A, Lecocq JP, Crystal RG,. Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin. Nucleic Acids Res 1991; 19: 5417-5423.
91. Painter RG, Valentine VG, Lanson NA, Jr, Leidal K, Zhang Q, Lombard G, Thompson C, Viswanathan A, Nauseef WM, Wang G, et al., CFTR Expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis. Biochemistry 2006; 45: 10260-10269.
92. Painter RG, Bonvillain RW, Valentine VG, Lombard GA, LaPlace SG, Nauseef WM, Wang G,. The role of chloride anion and CFTR in killing of Pseudomonas aeruginosa by normal and CF neutrophils. J Leukoc Biol 2008; 83: 1345-1353.
93. Painter RG, Marrero L, Lombard GA, Valentine VG, Nauseef WM, Wang G,. CFTR-mediated halide transport in phagosomes of human neutrophils. J Leukoc Biol 2010; 87: 933-942.
94. Kirchner KK, Wagener JS, Khan TZ, Copenhaver SC, Accurso FJ,. Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis. Am J Respir Crit Care Med 1996; 154: 1426-1429.
95. Konstan MW, Walenga RW, Hilliard KA, Hilliard JB,. Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis 1993; 148: 896-901.
96. Konstan MW, Hilliard KA, Norvell TM, Berger M,. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994; 150: 448-454.
97. Lawrence R, Sorrell T,. Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet 1993; 342: 465-469.
98. Noah TL, Black HR, Cheng PW, Wood RE, Leigh MW,. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis 1997; 175: 638-647.
99. Muhlebach MS, Stewart PW, Leigh MW, Noah TL,. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999; 160: 186-191.
100. Balough K, McCubbin M, Weinberger M, Smits W, Ahrens R, Fick R,. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 1995; 20: 63-70.
101. Rowe SM, Jackson PL, Liu G, Hardison M, Livraghi A, Solomon GM, McQuaid DB, Noerager BD, Gaggar A, Clancy JP, et al., Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med 2008; 178: 822-831.
102. Bartling TR, Drumm ML,. Oxidative stress causes IL8 promoter hyperacetylation in cystic fibrosis airway cell models. Am J Respir Cell Mol Biol 2009; 40: 58-65.
103. Bartling TR, Drumm ML,. Loss of CFTR results in reduction of histone deacetylase 2 in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2009; 297: L35-L43.
104. Gaggar A, Hector A, Bratcher PE, Mall MA, Griese M, Hartl D,. The role of matrix metalloproteinases in cystic fibrosis lung disease. Eur Respir J 2011; 38: 721-727.
105. Bratcher PE, Weathington NM, Nick HJ, Jackson PL, Snelgrove RJ, Gaggar A,. MMP-9 cleaves SP-D and abrogates its innate immune functions in vitro. PLoS ONE 2012; 7: e41881.
106. Meyer KC, Zimmerman J,. Neutrophil mediators, pseudomonas, and pulmonary dysfunction in cystic fibrosis. J Lab Clin Med 1993; 121: 654-661.
107. Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, Sagel SD, Ramsey BW,. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 2007; 175: 822-828.
108. Sagel SD, Sontag MK, Wagener JS, Kapsner RK, Osberg I, Accurso FJ,. Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. J Pediatr 2002; 141: 811-817.
109. Birrer P, McElvaney NG, Rüdeberg A, Sommer CW, Liechti-Gallati S, Kraemer R, Hubbard R, Crystal RG,. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994; 150: 207-213.
110. Schuster A, Ueki I, Nadel JA,. Neutrophil elastase stimulates tracheal submucosa gland secretion that is inhibited by ICI 200,355. Am J Physiol 1992; 262: L86.
111. Sommerhoff CP, Nadel JA, Basbaum CB, Caughey GH,. Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. J Clin Invest 1990; 85: 682-689.
112. Smallman LA, Hill SL, Stockley RA,. Reduction of ciliary beat frequency in vitro by sputum from patients with bronchiectasis: a serine protease effect. Thorax 1984; 39: 663-667.
113. Tegner H, Ohlsson K, Toremalm NG, von Mecklenburg C,. Effect of human leukocyte enzymes on tracheal mucosa and mucociliary activity. Rhinology 1979; 17: 199-206.
114. Park JA, He F, Martin LD, Li Y, Chorley BN, Adler KB,. Human neutrophil elastase induces hypersecretion of mucin from well-differentiated human bronchial epithelial cells in vitro via a protein kinase C{delta}-mediated mechanism. Am J Pathol 2005; 167: 651-661.
115. Voynow JA, Young LR, Wang Y, Horger T, Rose MC, Fischer BM,. Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells. Am J Physiol 1999; 276: L835-L843.
116. McElvaney NG, Nakamura H, Birrer P, Hebert CA, Wong WL, Alphonso M, Baker JB, Catalano MA, Crystal RG,. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest 1992; 90: 1296-1301.
117. Nakamura H, Yoshimura K, McElvaney NG, Crystal RG,. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in human bronchial epithelial cell line. J Clin Invest 1992; 89: 1478-1484.
118. Caldwell RA, Boucher RC, Stutts MJ,. Neutrophil elastase activates near-silent epithelial Na+ channels and increases airway epithelial Na+ transport. Am J Physiol Lung Cell Mol Physiol 2005; 288: L813-L819.
119. Vandivier RW, Fadok VA, Hoffmann PR, Bratton DL, Penvari C, Brown KK, Brain JD, Accurso FJ, Henson PM,. Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Invest 2002; 109: 661-670.
120. Vandivier RW, Fadok VA, Ogden CA, Hoffmann PR, Brain JD, Accurso FJ, Fisher JH, Greene KE, Henson PM,. Impaired clearance of apoptotic cells from cystic fibrosis airways. Chest 2002; 121: 89S.
121. Le Gars M, Descamps D, Roussel D, Saussereau E, Guillot L, Ruffin M, Tabary O, Hong 45, Boulanger P, Paulais M, et al., Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivo. Am J Respir Crit Care Med 2013; 187: 170-179.
122. Berger M, Sorensen RU, Tosi MF, Dearborn DG, Doring G,. Complement receptor expression on neutrophils at an inflammatory site, the pseudomonas-infected lung in cystic fibrosis. J Clin Invest 1989; 84: L302-L313.
123. Tosi MF, Berger M,. Functional differences between the 40 kDa and 50 to 70 kDa IgG Fc receptors on human neutrophils revealed by elastase treatment and antireceptor antibodies. J Immunol 1988; 141: 2097-2103.
124. Tosi MF, Zakem H, Berger M,. Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest 1990; 86: 300-308.
125. Tosi MF, Zakem H,. Surface expression of Fc gamma receptor III (CD 16) on chemoattractant-stimulated neutrophils is determined by both surface shedding and translocation from intracellular storage compartments. J Clin Invest 1992; 90: 462-470.
126. Brennan S, Sly PD, Gangell CL, Sturges N, Winfield K, Wikstrom M, Gard S, Upham JW, AREST CF,. Alveolar macrophages and CC chemokines are increased in children with cystic fibrosis. Eur Respir J 2009; 34: 655-661.
127. Bruscia EM, Zhang PX, Ferreira E, Caputo C, Emerson JW, Tuck D, Kraus DS, Egan ME,. Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator-/- mice. Am J Respir Cell Mol Biol 2009; 40: 295-304.
128. Bruscia EM, Zhang PX, Satoh A, Caputo C, Medzhitov R, Shenoy A, Egan ME, Kraus DS,. Abnormal trafficking and degradation of TLR4 underlie the elevated inflammatory response in cystic fibrosis. J Immunol 2011; 186: 6990-6998.
129. Meyer M, Huaux F, Gavilanes X, van den BrÛle S, Lebecque P, Lo Re S, Lison D, Scholte B, Wallemacq P, Leal T,. Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. Am J Respir Cell Mol Biol 2009; 41: 590-602.
130. Deriy LV, Gomez EA, Zhang G, Beacham DW, Hopson JA, Gallan AJ, Shevchenko PD, Bindokas VP, Nelson DJ,. Disease-causing mutations in the cystic fibrosis transmembrane conductance regulator determine the functional responses of alveolar macrophages. J Biol Chem 2009; 284: 35926-35938.
131. Radtke AL, Anderson KL, Davis MJ, DiMagno MJ, Swanson JA, O'Riordan MX,. Listeria monocytogenes exploits cystic fibrosis transmembrane conductance regulator (CFTR) to escape the phagosome. Proc Natl Acad Sci USA 2011; 108: 1633-1638.
132. Sorio C, Buffelli M, Angiari C, Ettorre M, Johansson J, Vezzalini M, Viviani L, Ricciardi M, Verzè G, Assael BM, et al., Defective CFTR expression and function are detectable in blood monocytes: development of a new blood test for cystic fibrosis. PLoS ONE 2011; 6: e22212.
133. Del Porto P, Cifani N, Guarnieri S, Di Domenico EG, Mariggiò MA, Spadaro F, Guglietta S, Anile M, Venuta F, Quattrucci S, et al., Dysfunctional CFTR alters the bactericidal activity of human macrophages against Pseudomonas aeruginosa. PLoS ONE 2011; 6: e19970.
134. Di A, Brown ME, Deriy LV, Li C, Szeto FL, Chen Y, Huang P, Tong J, Naren AP, Bindokas V, et al., CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol 2006; 8: 933-944.
135. Haggie PM, Verkman AS,. Cystic fibrosis transmembrane conductance regulator-independent phagosomal acidification in macrophages. J Biol Chem 2007; 282: 31422-31428.
136. Liu G, Wang J, Park YJ, Tsuruta Y, Lorne EF, Zhao X, Abraham E,. High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. J Immunol 2008; 181: 4240-4246.
137. Soltys J, Bonfield T, Chmiel J, Berger M,. Functional IL-10 deficiency in the lung of cystic fibrosis (cftr -/-) and IL-10 knockout mice causes increased expression and function of B7 costimulatory molecules on alveolar Macrophages. J Immunol 2002; 168: 1903-1910.
138. Raga S, Julià MR, Crespí C, Figuerola J, Martínez N, Milà J, Matamoros N,. Gammadelta T lymphocytes from cystic fibrosis patients and healthy donors are high TNF-alpha and IFN-gamma-producers in response to Pseudomonas aeruginosa. Respir Res 2003; 4: 9.
139. Tiringer K, Treis A, Fucik P, Gona M, Gruber S, Renner S, Dehlink E, Nachbaur E, Horak F, Jaksch P, et al., A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2013; 187: 621-629.
140. Bayes HK, Bicknell S, MacGregor G, Evans TJ,. T helper cell subsets specific for Pseudomonas aeruginosa in healthy individuals and patients with cystic fibrosis. PLoS ONE 2014; 9: e90263.
141. Dubin PJ, McAllister F, Kolls JK,. Is cystic fibrosis a TH17 disease? Inflamm Res 2007; 56: 221-227.
142. Dubin PJ, Kolls JK,. IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol 2007; 292: L519-L528.
143. McAllister F, Henry A, Kreindler JL, Dubin PJ, Ulrich L, Steele C, Finder JD, Pilewski JM, Carreno BM, Goldman SJ, et al., Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol 2005; 175: 404-412.
144. Tan HL, Rosenthal M,. IL-17 in lung disease: friend or foe? Thorax 2013; 68: 788-790.
145. Ferretti S, Bonneau O, Dubois GR, Jones CE, Trifilieff A,. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol 2003; 170: 2106-2112.
146. Hsu DP, van Heeckeren A, Schlucter M, Xue W, Davis PB,. IL-17 targeted antibody treatment increases the excessive pulmonary inflammation in CF mice. Pediatr Pulmonol 2006; S29: 256.
147. Van Asperen P, Mellis CM, South RT, Simpson SJ,. Bronchial reactivity in cystic fibrosis with normal pulmonary function. Am J Dis Child 1981; 135: 815-819.
148. Sanchez I, Powell RE, Pasterkamp H,. Wheezing and airflow obstruction during methacholine challenge in children with cystic fibrosis and in normal children. Am Rev Respir Dis 1993; 147: 705-709.
149. Vandebrouck C, Melin P, Norez C, Robert R, Guibert C, Mettey Y, Becq F,. Evidence that CFTR is expressed in rat tracheal smooth muscle cells and contributes to bronchodilation. Respir Res 2006; 7: 113.
150. Michoud MC, Robert R, Hassan M, Moynihan B, Haston C, Govindaraju V, Ferraro P, Hanrahan JW, Martin JG,. Role of the cystic fibrosis transmembrane conductance channel in human airway smooth muscle. Am J Respir Cell Mol Biol 2009; 40: 217-222.
151. Regamey N, Ochs M, Hilliard TN, Mühlfeld C, Cornish N, Fleming L, Saglani S, Alton EW, Bush A, Jeffery PK, et al., Increased airway smooth muscle mass in children with asthma, cystic fibrosis, and non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2008; 177: 837-843.
152. Hays SR, Ferrando RE, Carter R, Wong HH, Woodruff PG,. Structural changes to airway smooth muscle in cystic fibrosis. Thorax 2005; 60: 226-228.
153. Darrah R, McKone E, O'Connor C, Rodgers C, Genatossio A, McNamara S, Gibson R, Stuart Elborn J, Ennis M, Gallagher CG, et al., EDNRA variants associate with smooth muscle mRNA levels, cell proliferation rates, and cystic fibrosis pulmonary disease severity. Physiol Genomics 2010; 41: 71-77.
154. Hartl D, Griese M, Kappler M, Zissel G, Reinhardt D, Rebhan C, Schendel DJ, Krauss-Etschmann S,. Pulmonary T(H) 2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol 2006; 117: 204-211.
155. Cosgrove S, Chotirmall SH, Greene CM, McElvaney NG,. Pulmonary proteases in the cystic fibrosis lung induce interleukin 8 expression from bronchial epithelial cells via a heme/meprin/epidermal growth factor receptor/Toll-like receptor pathway. J Biol Chem 2011; 286: 7692-7704.
156. Jackson PL, Xu X, Wilson L, Weathington NM, Clancy JP, Blalock JE, Gaggar A,. Human neutrophil elastase-mediated cleavage sites on MMP-9 and TIMP-1: implications to cystic fibrosis proteolytic dysfunction. Mol Med 2010; 16: 159-166.
157. Weldon S, McNally P, McElvaney NG, Elborn JS, McAuley DF, Wartelle J, Belaaouaj A, Levine RL, Taggart CC, et al., Decreased levels of secretory leucoprotease inhibitor in the pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degredation. J Immunol 2009; 183: 8146-8156.
158. McElvaney NG, Hubbard RC, Birrer P, Chernick MS, Caplan DB, Frank MM, Crystal RG,. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 1991; 337: 392-394.
159. Cantin AM, Berthiaume Y, Cloutier D, Martel M,. Prolastin aerosol therapy and sputum taurine in cystic fibrosis. Clin Invest Med 2006; 29: 201-207.
160. Griese M, Latzin P, Kappler M, Weckerle K, Heinzlmaier T, Bernhardt T, Hartl D,. Alpha1-antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007; 29: 240-250.
161. Nichols D, Donalson SH, Dorkin H, Flume PA, Gaggar A, Chmiel J, Griffin R,. A 3 week dose escalation, randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, and possible efficacy of 100 mg or 200 mg of once daily inhaled alpha-1 HC in cystic fibrosis (CF). Pediatr Pulmonol 2014; S38: 316.
162. Kettle AJ, Turner R, Gangell CL, Harwood DT, Khalilova IS, Chapman AL, Winterbourn CC, Sly PD, AREST CF,. Oxidation contributes to low glutathione in the airways of children with cystic fibrosis. Eur Respir J 2014; 44: 122-129.
163. Reid DW, Misso N, Aggarwal S, Thompson PJ, Walter EH,. Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis. Respirology 2007; 12: 63-69.
164. Ziady AG, Hansen J,. Redox balance in cystic fibrosis. Int J Biochem Cell Biol 2014; 52: 113-123.
165. Nichols DP, Ziady AG, Shank SL, Eastman JF, Davis PB,. The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease. Am J Physiol Lung Cel Mol Physiol 2009; 297: L828-L836.
166. de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, et al., Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013; 369: 2492-2503.
167. Chmiel JF, Ziady AG, Cantin A, Comhair S, Hazen SL, Schluchter MD, Margevicius S, Bucur C, Campbell PW, Konstan MW,. A pilot study evaluating the effect of sulforaphane in broccoli sprouts on Nrf2 activation, glutathione, markers of oxidative stress, and neutrophil migration in healthy volunteers and subjects with CF. Pediatr Pulmonol 2012; S35: 250.
168. Chandler JD, Min E, Huang J, Nichols DP, Day BJ,. Nebulized thiocyanate improves lung infection outcomes in mice. Br J Pharmacol 2013; 169: 1166-1177.
169. Chandler JD, Min E, Huang J, McElroy CS, Dickerhof N, Mocatta T, Fletcher AA, Evans CM, Liang L, Patel M, et al., Anti-inflammatory and anti-microbial effects of thiocyanate in a cystic fibrosis mouse model. Am J Respir Cell Mol Biol 2014;[In press].
170. Lorentzen D, Durairaj L, Pezzulo AA, Nakano Y, Saunspach J, Stoltz DA, Zamba G, McCray PB, Jr, Zabner J, Welsh MJ, et al., Concentration of the antibacterial precursor thiocyanate in cystic fibrosis airway secretions. Free Radic Biol Med 2011; 50: 1144-1150.
171. Conner GE, Wijkstrom-Frei C, Randell SH, Fernandez VE, Salathe M,. The lactoperoxidase system links anion transport to host defense in cystic fibrosis. FEBS Lett 2007; 581: 271-278.
172. Chandler JD, Nichols DP, Nick JA, Hondal RJ, Day BJ,. Selective metabolism of hypothiocyanous acid by mammalian thioredoxin reductase promotes lung innate immunity and antioxidant defense. J Biol Chem 2013; 288: 18421-18428.
173. Xu Y, Szep S, Lu Z,. The antioxidant role of thiocyanate in the pathogenesis of cystic fibrosis and other inflammation-related diseases. Proc Natl Acad Sci USA 2009; 106: 20515-20519.
174. Moreau-Marquis S, Coutermarsh B, Stanton BA,. Combination of hypothiocyanite and lactoferrin (ALX-109) enhances the ability of tobramycin and aztreonam to eliminate Pseudomonas aeruginosa biofilms growing on cystic fibrosis airway epithelial cells. J Antimicrob Chemother 2015; 70: 160-166.
175. Schulz V,. Clinical pharmacokinetics of nitroprusside, cyanide, thiosulphate and thiocyanate. Clin Pharmacokinet 1984; 9: 239-251.
176. Chandler JD, Day BJ,. Thiocyanate: a potentially useful therapeutic agent with host defense and antioxidant properties. Biochem Pharmacol 2012; 84: 1381-1387.
177. Freedman SD, Blanco PG, Zaman MM, Shea JC, Ollero M, Hopper IK, Weed DA, Gelrud A, Regan MM, Laposata M, et al., Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004; 350: 560-569.
178. Freedman SD, Weinstein D, Blanco PG, Martinez-Clark P, Urman S, Zaman M, Morrow JD, Alvarez JG,. Characterization of LPS-induced lung inflammation in cftr-/- mice and the effect of docosahexaenoic acid. J Appl Physiol (1985) 2002; 92: 2169-2176.
179. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN,. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 2003; 278: 14677-14687.
180. Yang Y, Cheng Y, Lian QQ, Yang L, Qi W, Wu DR, Zheng X, Liu YJ, Li WJ, Jin SW, et al., Contribution of CFTR to alveolar fluid clearance by lipoxin A4 via PI3K/Akt pathway in LPS-induced acute lung injury. Mediators Inflamm 2013; 2013: 862628.
181. Al-Alawi M, Buchanan P, Verriere V, Higgins G, McCabe O, Costello RW, McNally P, Urbach V, Harvey BJ,. Physiological levels of lipoxin A4 inhibit ENaC and restore airway surface liquid height in cystic fibrosis bronchial epithelium. Physiol Rep 2014; 2.
182. Higgins G, Buchanan P, Perriere M, Al-Alawi M, Costello RW, Verriere V, McNally P, Harvey BJ, Urbach V,. Activation of P2RY11 and ATP release by lipoxin A4 restores the airway surface liquid layer and epithelial repair in cystic fibrosis. Am J Respir Cell Mol Biol 2014; 51: 178-190.
183. Ringholz FC, Buchanan PJ, Clarke DT, Millar RG, McDermott M, Linnane B, Harvey BJ, McNally P, Urbach V,. Reduced 15-lipoxygenase 2 andS lipoxin A4/leukotriene B4 ratio in children with cystic fibrosis. Eur Respir J 2014; 44: 394-404.
184. Bravo E, Napolitano M, Valentini SB, Quattrucci S,. Neutrophil unsaturated fatty acid release by GM-CSF is impaired in cystic fibrosis. Lipids Health Dis 2010; 9: 129.
185. Chiron R, Grumbach YY, Quynh NV, Verriere V, Urbach V,. Lipoxin A(4) and interleukin-8 levels in cystic fibrosis sputum after antibiotherapy. J Cyst Fibros 2008; 7: 463-468.
186. Snelgrove RJ, Jackson PL, Hardison MT, Noerager BD, Kinloch A, Gaggar A, Shastry S, Rowe SM, Shim YM, Hussell T, et al., A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation. Science 2010; 330: 90-94.
187. Schmitt L, Wiebel M, Frese F, Dehnert C, Zugck C, Bärtsch P, Mairbäurl H,. Exercise reduces airway sodium ion reabsorption in cystic fibrosis but not in exercise asthma. Eur Respir J 2011; 37: 342-348.
188. Hebestreit A, Kersting U, Basler B, Jeschke R, Hebestreit H,. Exercise inhibits epithelial sodium channels in patients with cystic fibrosis. Am J Respir Crit Care Med 2001; 164: 443-446.
189. Button B, Picher M, Boucher RC,. Differential effects of cyclic and constant stress on ATP release and mucociliary transport by human airway epithelia. J Physiol 2007; 580: 577-592.
190. Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA,. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol 2011; 11: 607-615.
191. Walsh NP, Gleeson M, Shephard RJ, Gleeson M, Woods JA, Bishop NC, Fleshner M, Green C, Pedersen BK, Hoffman-Goetz L, et al., Position statement. Part one: immune function and exercise. Exerc Immunol Rev 2011; 17: 6-63.
192. da Silva RA, Almeida FM, Olivo CR, Saraiva-Romanholo BM, Perini A, Martins MA, Carvalho CR,. Comparison of the effects of aerobic conditioning before and after pulmonary allergic inflammation. Inflammation 2015; 38: 1229-1238.
193. Olivo CR, Miyaji EN, Oliveira ML, Almeida FM, Lourenço JD, Abreu RM, Arantes PM, Lopes FD, Martins MA,. Aerobic exercise attenuates pulmonary inflammation induced by Streptococcus pneumoniae. J Appl Physiol 2014; 117: 998-1007.
194. Vieira RP, Silva RA, Oliveira-Junior MC, Greiffo FR, Ligeiro-Oliveira AP, Martins MA, Carvalho CR,. Exercise deactivates leukocytes in asthma. Int J Sports Med 2014; 35: 629-635.
195. Reis Gonçalves CT, Reis Gonçalves CG, de Almeida FM, Lopes FD, dos Santos Durão AC, dos Santos FA, da Silva LF, Marcourakis T, Castro-Faria-Neto HC, Vieira Rde P, et al., Protective effects of aerobic exercise on acute lung injury induced by LPS in mice. Crit Care 2012; 16: R199.
196. Gleeson M, Walsh NP,. British Association of Sport and Exercise Sciences. The BASES expert statement on exercise, immunity, and infection. J Sports Sci 2012; 30: 321-324.
197. van de Weert-van Leeuwen PB, de Vrankrijker AM, Fentz J, Ciofu O, Wojtaszewski JF, Arets HG, et al., Effect of long-term voluntary exercise wheel running on susceptibility to bacterial pulmonary infections in a mouse model. PLoS ONE 2013; 8: e82869.
198. Tirakitsoontorn P, Nussbaum E, Moser C, Hill M, Cooper DM,. Fitness, acute exercise, and anabolic and catabolic mediators in cystic fibrosis. Am J Respir Crit Care Med 2001; 164: 1432-1437.
199. Ploeger HE, Takken T, de Greef MH, Timmons BW,. The effects of acute and chronic exercise on inflammatory markers in children and adults with a chronic inflammatory disease: a systematic review. Exerc Immunol Rev 2009; 15: 6-41.
200. Moeller A, Stampfli SF, Rueckert B, Rechsteiner T, Hamacher J, Wildhaber JH,. Effects of a short-term rehabilitation program on airway inflammation in children with cystic fibrosis. Pediatr Pulmonol 2010; 45: 541-551.
201. Nikolaizik WH, Simon HU, Iseli P, Blaser K, Schoni MH,. Effect of 3 weeks' rehabilitation on neutrophil surface antigens and lung function in cystic fibrosis. Eur Respir J 2000; 15: 942-948.
202. Gruber W, Orenstein DM, Braumann KM, Huls G,. Health-related fitness and trainability in children with cystic fibrosis. Pediatr Pulmonol 2008; 43: 953-964.
203. Hebestreit H, Kieser S, Junge S, Ballmann M, Hebestreit A, Schindler C, Schenk T, Posselt HG, Kriemler S,. Long-term effects of a partially supervised conditioning programme in cystic fibrosis. Eur Respir J 2010; 35: 578-583.
204. Moorcroft AJ, Dodd ME, Morris J, Webb AK,. Individualised unsupervised exercise training in adults with cystic fibrosis: a 1 year randomised controlled trial. Thorax 2004; 59: 1074-1080.
205. Kriemler S, Kieser S, Junge S, Ballmann M, Hebestreit A, Schindler C, Stüssi C, Hebestreit H,. Effect of supervised training on FEV1 in cystic fibrosis: a randomised controlled trial. J Cyst Fibros 2013; 12: 714-720.
206. Klijn PH, Oudshoorn A, van der Ent CK, van der Net J, Kimpen JL, Helders PJ,. Effects of anaerobic training in children with cystic fibrosis: a randomized controlled study. Chest 2004; 125: 1299-1305.
207. van de Weert-van Leeuwen PB, Slieker MG, Hulzebos HJ, Kruitwagen CL, van der Ent CK, Arets HG,. Chronic infection and inflammation affect exercise capacity in cystic fibrosis. Eur Respir J 2012; 39: 893-898.
208. Hebestreit H, Schmid K, Kieser S, Junge S, Ballmann M, Roth K, Hebestreit A, Schenk T, Schindler C, Posselt HG, et al., Quality of life is associated with physical activity and fitness in cystic fibrosis. BMC Pulm Med 2014; 14: 26.
209. Nixon PA, Orenstein DM, Kelsey SF, Doershuk CF,. The prognostic value of exercise testing in patients with cystic fibrosis. N Engl J Med 1992; 327: 1785-1788.
210. van de Weert-van Leeuwen PB, Hulzebos HJ, Werkman MS, Michel S, Vijftigschild LA, van Meegen MA, van der Ent CK, Beekman JM, Arets HG,. Chronic inflammation and infection associate with a lower exercise training response in cystic fibrosis adolescents. Respir Med 2014; 108: 445-452.